Pnömokok Aşısı Olduğu Bilinen Hastalarda Covid 19 Seyri

Abstract

Amaç: 2019 yılı sonlarında ortaya çıkan ve halen tüm dünyayı etkileyen coronavirüs pandemisi ciddi sayıda vaka ve ölümlere neden olmaktadır. Covid-19 aşılarının dünyada hızla yapılmaya başlandığı bu dönemde diğer aşılar da önemsenmektedir. Özellikle pnömokok aşısının etkileri bu dönemde merak edilmektedir. Bu çalışmada pnömokok aşısı olduğu bilinen 16 vakanın covid 19 dönemindeki verileri incelendi. Metot: 65 yaş üstü 200 kişilik covid 19 pozitif hastanın içinden pnömokok aşısı olduğu bilinen 16 vakanın verilerine hastane sistemleri ile ulusal sağlık sisteminden yararlanılarak ulaşıldı. Bu vakalara ait kronik hastalık ile covid dönemi prognostik faktörleri frekans tabloları ile verildi. Ayrıca tüm vakalar detaylı bir tablo ile çözümlendi. Bulgular: 16 vakanın hepsinde kronik hastalık tanısı vardı. Hastalardan dördünün durumu ölümle sonuçlandı. Vakaların çoğu PCR pozitifti (%68.75) ve yine %68.75 kişide BT Covid ile uyumluydu. Vakalardan 14 tanesi hastaneye yatırılarak tedavi edildi. 1 tanesi ayaktan takip edildi. Bir vaka ise ölü olarak acil servise getirilmişti. Sonuç: Son derece önemli olan ve covid 19 döneminde önemi gittikçe artan pnömokok aşısının önceden yapıldığı bilinen 16 vakaya ait veriler verildi. Bu çalışmanın büyük ölçekli çalışmalara kaynak niteliğinde olacağı öngörülmektedir.

Keywords

• Aşı, Pnömokok aşısı, Covid-19, Koronavirüs, Pandemi

COVID-19 Course in Patients Receiving Pneumococcal Vaccine

Abstract

Objective: The coronavirus pandemic emerged at the end of 2019 and still affects the whole world, causing severe deaths. The COVID-19 vaccine is highly anticipated, but the emphasis is also given to other vaccines. In this study, the data of 16 cases known having received a pneumococcal vaccine during the COVID-19 period were examined. Methods: Of the 200 COVID-19 cases aged over 65, data of 16 patients who have had pneumococcal vaccination were accessed using the hospital health registry and the national health system records (https://enabiz.gov.tr/). Prognostic factors and COVID-19-related findings of these patients were given in frequency tables. In addition, all raw data were presented in a detailed table. Results: Most of the cases were PCR positive (68.75%), and in 68.75% of the persons, the CT was compatible with COVID-19. Fourteen of the cases were treated by hospitalization. One patient was followed as an outpatient, and one case had already died when brought to the emergency room. Conclusion: Data on cases known to have received the pneumococcal vaccine, which became important during the COVID-19 outbreak, were presented. This work will motivate researchers to conduct large-scale studies.

Keywords

• Vaccine
• Pneumococcal vaccine
• Covid-19
• Coronavirus
• Pandemic

References

1. 1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020.
2. 2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020.
3. 3. Organization WH. Health Topics. Coronavírus 2020. Available from: https://www. who. int/healthtopics/coronavirus# tab= tab_3. Acesso em.
4. 4. Khadka S, Hashmi FK, Usman M. Preventing COVID-19 in low-and middle-income countries. Drugs & Therapy Perspectives. 2020:1-3.
5. 5. Organization WH. WHO Coronavirus Disease (COVID-19) Dashboard 2020. Available from: https://covid19.who.int/.
6. 6. Ahn D-G, Shin H-J, Kim M-H, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). 2020.
7. 7. Paguio JA, Yao JS, Dee EC. Silver lining of COVID-19: Heightened global interest in pneumococcal and influenza vaccines, an infodemiology study. Vaccine. 2020;38(34):5430-5.
8. 8. Sultana J, Mazzaglia G, Luxi N, et al. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks and public health considerations. Expert review of vaccines. 2020.

9. 9. Moulton L, O'Brien K, Reid R, et al. Evaluation of the indirect effects of a pneumococcal vaccine in a community-randomized study. Journal of biopharmaceutical statistics. 2006;16(4):453-62.
10. 10. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane database of systematic reviews. 2013(1).
11. 11. Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008;26(33):4284-9.
12. 12. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. New England Journal of Medicine. 2003;348(18):1747-55.
13. 13. Ministry of Health. Pneumococcal Disease 2020. Available from: https://hsgm.saglik.gov.tr/tr/kronikhastaliklar-haberler/65-yas-ustu-bireylerde-bagisiklama.html.
14. 14. Matanock A, Lee G, Gierke R, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged≥ 65 years: updated recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report. 2019;68(46):1069.
15. 15. MacIntyre CR, Chughtai AA, Barnes M, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1) pdm09. BMC infectious diseases. 2018;18(1):637.
16. 16. Chien Y-W, Klugman KP, Morens DM. Bacterial pathogens and death during the 1918 influenza pandemic. New England Journal of Medicine. 2009;361(26):2582-3.
17. 17. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.
18. 18. Mikami T, Miyashita H, Yamada T, et al. Risk factors for mortality in patients with COVID-19 in New York City. Journal of general internal medicine. 2020:1-10.